Oncotarget

Research Papers:

Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health

Elisabetta De Matteis, Maria Rosaria Tumolo _, Paolo Tarantino, Mariangela Ciccarese, Tiziana Grassi, Francesco Bagordo, Maria Rita De Giorgio, Emanuele Rizzo and Graziana Ronzino

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:134-141. https://doi.org/10.18632/oncotarget.28561

Metrics: PDF 218 views  |   Full Text 819 views  |   ?  


Abstract

Elisabetta De Matteis1, Maria Rosaria Tumolo2, Paolo Tarantino3, Mariangela Ciccarese4, Tiziana Grassi2, Francesco Bagordo5, Maria Rita De Giorgio1, Emanuele Rizzo2 and Graziana Ronzino6

1 U.O.S.V.D. Oncological Screenings, “Vito Fazzi” Hospital, Lecce, Italy

2 Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy

3 U.O.C. Medical Genetics, “Vito Fazzi” Hospital, Lecce, Italy

4 Strategic Regional Agency for Health and Social of Puglia, Bari, Italy

5 Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, Bari, Italy

6 Oncology Unit, “Vito Fazzi” Hospital, Lecce, Italy

Correspondence to:

Maria Rosaria Tumolo, email: [email protected]

Keywords: ovarian cancer; BRCA1; BRCA2; mutation

Received: November 24, 2023     Accepted: January 23, 2024     Published: February 22, 2024

Copyright: © 2024 De Matteis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Objectives: The aim of this exploratory, descriptive study was to characterize the deleterious BRCA1 and BRCA2 variants evaluated by genetic testing in a group of Ovarian cancer patients living in the Salento peninsula (Southern Italy).

Methods: From June 2014 to July 2023, patients with histologically confirmed high-grade serous carcinoma, fallopian tube, or primary peritoneal cancer who were referred to Lecce Familial Cancer Clinic were considered. BRCA-mutation genetic testing was performed on these patients. Socio-demographic data and cancer epidemiology were assessed, and Next Generation Sequencing and Sanger DNA sequencing were performed.

Results: The median age at the diagnosis of 332 ovarian cancer patients collected was 57 years. The pedigree analyses showed that 28.6% had familial cases and 39.7% had sporadic cases. Of the 319 patients submitted to genetic testing, 29.8% were carriers of BRCA1/2 mutation, 75.8% at BRCA1 and 24.2% at BRCA2 gene. Of the 21 BRCA1 mutations, the variant c.5266dupC was the most frequent alteration (28.4%). With respect to BRCA2, 13 mutations were found and the variant c.9676delT was the most frequently recorded (6.3%).

Conclusions: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28561